正在加载视频...
视频加载失败
The FDA’s recent recommendations on peptides are a *significant* setback for new and existing companies being built around the expectation that they will be able to sell compounded peptides. That’s because the 503A Bulks List is basically a pathway that lets compounding pharmacies use certain bulk drug substances to... show more
48,450 次观看 • 1 个月前 •via X (Twitter)
0 条评论
暂无评论
原始帖子的评论将显示在这里

